Method for producing radioactive metal-labeled antibody

IN604796BActive Publication Date: 2026-10-01NIHON MEDI PHYSICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202247027115
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-18
Filing Date
2022-05-11
Publication Date
2026-10-01
Estimated Expiration
2040-10-16

AI Technical Summary

Technical Problem

Existing methods for producing radioactive metal-labeled antibodies often require heating, which can denature the antibodies and are not optimized for mild reaction conditions, leading to inefficiencies in labeling efficiency.

Method used

A method involving a click reaction between a radioactive metal complex and an antibody site-specifically modified with a peptide, using atomic groups capable of click reactions such as azide or trans-cyclooctene, to form a stable triazole or pyridazine structure, ensuring efficient labeling under mild conditions.

Benefits of technology

This approach allows for high labeling efficiency of radioactive metals on antibodies without denaturing them, maintaining antigen specificity and enabling rapid production of radioactive metal-labeled antibodies with high radiochemical purity and yield, even with short-half-life isotopes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The method for producing a radioactive metal-labeled antibody of the present invention has a step for click reacting a radioactive metal complex with an antibody site-specifically modified by a peptide to generate a radioactive metal-labeled antibody. The click reaction is carried out between a first atomic group with which the radioactive metal complex is equipped and a second atomic group linked directly or indirectly to the peptide. The second atomic group is an atomic group including an azide or an atomic group including trans-cyclooctene.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present invention relates to a production method of aradioactive metal-labeled antibody.BACKGROUND ART

[0002] An antibody is used as a reagent for detecting a targetmolecule, a diagnostic agent, or a pharmaceutical product fortreating a disease by utilizing the specificity of the antibodyfor a target molecule. To further improve the detectionperformance and therapeutic effect, studies on antibodies boundto radionuclides and drugs are underway.

[0003] Patent Literature 1 describes a peptide containing anamino acid sequence consisting of 13 to 17 amino acid residuesand capable of binding to a human antibody. This document alsodescribes that the above-mentioned peptide can be modified witha labeling substance such as a complex containing aradioisotope or a drug such as an anticancer agent, and that acomplex of the peptide and an antibody can be formed.

[0004] Patent Literature 2 describes a conjugate of an antibodyand a peptide modified by the DTPA complex of 111In, which is aradioactive metal. It is also described that this antibodyconjugate specifically binds to a target molecule expressed ina tumor.CITATION LISTPATENT LITERATURES

[0005] Patent Literature 1: WO 2016 / 186206Patent Literature 2: WO 2017 / 217347Patent Literature 3: WO 2019 / 125982SUMMARY OF INVENTION

[0006] When producing an antibody bound with a radioactive metalcomplex, it may be necessary to heat the reaction system inorder to increase the efficiency of complex formation,depending on the combination of the ligand and the radioactivemetal to be used. However, under this condition, the desiredantibody cannot be obtained since the antibody is denatured byheating. Patent Literatures 1 and 2 do not study the reactionconditions for solving such problem.

[0007] Therefore, the problem of the present invention is toprovide a production method of a radioactive metal-labeledantibody superior in the labeling efficiency of radioactivemetals for antibodies even under mild reaction conditions.

[0008] The present invention provides a method for producing aradioactive metal-labeled antibody comprising a step ofconducting a click reaction of a radioactive metal complex andan antibody site-specifically modified with a peptide toproduce the radioactive metal-labeled antibody, wherein theclick reaction is performed between a first atomic group of theradioactive metal complex and a second atomic group directly orindirectly linked to the peptide, and the second atomic groupis an atomic group containing an azide group, or an atomicgroup containing trans-cyclooctene.

[0009] In addition, the present invention provides a radioactivemetal-labeled antibody site-specifically modified with apeptide,wherein the radioactive metal complex is directly orindirectly linked to the peptide, and a triazole skeletoncontainingstructure represented by the following formula (10a)is present between the peptide and the radioactive metalcomplex, or a pyridazine skeleton-containing structure ispresent between the peptide and the radioactive metal complex:

[0010]

[0011] wherein R1A is a binding site with a modified site or a chelatesite, and R2A is a binding site with a peptide.

[0012] In addition, the present invention provides a chelatelinker comprising a chelate site coordinated to a radioactivemetal, and a modified site having a first atomic group capableof click reaction, wherein the first atomic group is an atomicgroup represented by the following formula (1a) or (1b):

[0013]

[0014] in the formula (1a), R1 is a binding site with a modified siteor a chelate site, and in the formula (1b), one of R3 and R4 isa binding site with a modified site or a chelate site, and theother is a hydrogen atom, a methyl group, a phenyl group or apyridyl group.

[0015] In addition, the present invention provides a peptidemodifiedantibody represented by the following formula (i) andsite-specifically modified by a peptide comprising an aminoacid sequence consisting of 13 to 17 amino acid residues, whichantibody comprisinga second atomic group capable of click reaction at the Nterminalor C-terminal of the peptide, wherein the secondatomic group is an atomic group represented by the followingformula (2a) or (2b):(Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd)... (i)wherein Xa, Xb, Xc, and Xd are continuous X in the number of a,continuous X in the number of b, continuous X in the number ofc, and continuous X in the number of d, respectively,X is an amino acid residue having neither a thiol group nor ahaloacetyl group in the side chain,a, b, c and d are each independently an integer of not lessthan one and not more than 5, and satisfy a+b+c+d14,Xaa1 and Xaa3 are each independently an amino acid residuederived from an amino acid having a thiol group in the sidechain, and they are bonded via a disulfide bond or theirsulfide groups are bonded via a linker, orone is an amino acid residue derived from an amino acid havinga thiol group in the side chain and the other is an amino acidresidue derived from an amino acid having a haloacetyl group inthe side chain, and they are bonded via a thioether bond, andXaa2 is a lysine residue, an arginine residue, a cysteineresidue, an aspartic acid residue, a glutamic acid residue, a2-aminosuberic acid, or a diamino propionic acid,

[0016]

[0017] in the formula (2a), R2 is a binding site with the N-terminalor C-terminal of the peptide, and in the formula (2b), R5 is abinding site with the N-terminal or C-terminal of the peptide.

[0018] According to the present invention, the labelingefficiency of a radioactive metal for an antibody is superioreven under mild reaction conditions.DESCRIPTION OF EMBODIMENTS

[0019] In the following, the production method of a radioactivemetal-labeled antibody of the present invention is explainedbased on preferred embodiments thereof.

[0020] The production method of the present invention includes astep of producing a radioactive metal-labeled antibody(labeling step) by a click reaction of a radioactive metalcomplex and an antibody site-specifically modified with apeptide (hereinafter to be also simply referred to as a"peptide-modified antibody"). The details of the radioactivemetal and a complex thereof, and the peptide are describedlater.

[0021] The radioactive metal complex and the peptide-modifiedantibody each have an atomic group capable of click reaction,and these atomic groups react with each other to allow theradioactive metal complex and the peptide-modified antibody tobind to each other. That is, the click reaction in this stepis performed between the first atomic group contained in theradioactive metal complex and the second atomic group directlyor indirectly linked to the peptide in the peptide-modifiedantibody.

[0022] The "directly or indirectly" refers to whether there is alinker structure described later between the second atomicgroup and the peptide. "Directly" means not having a linkerstructure, and more specifically means that the second atomicgroup is bonded to the N-terminal or C-terminal of the peptidenot via a linker structure. "Indirectly" means having a linkerstructure, and more specifically means that the second atomicgroup is bonded to the N-terminal or C-terminal of the peptidevia a linker structure. In either "directly" or "indirectly"embodiment, the second atomic group is preferably bonded to theN-terminal side of the peptide.

[0023] The aforementioned linker structure is represented by thefollowing formula (S1).**-((L1)m-Z)k-L2-AG2... (S1)wherein ** is a binding site with the N-terminal or C-terminalof a peptide,L1 is a linker site of polyethylene glycol (PEG),m is an integer of not less than 1 and not more than 50,Z is a second linker site that binds (L1)m and L2,k is 0 or 1,L2 is a second PEG linker site, andAG2 is a second atomic group.

[0024] In the aforementioned formula (S1), the structure of Z isnot particularly limited as long as it is a linker structurethat binds (L1)m and L2 to each other, and includes, for example,an amino acid sequence consisting of not less than 1 and notmore than 5 amino acid residues. In this case, the amino acidsequence contained in Z preferably contains a cysteine residue,and is more preferably bonded to L2 via a thioether groupformed by the bond between the thiol group of the cysteineresidue and a maleimide group.

[0025] In the present invention, the PEG linker siteconstituting L2 preferably has the structure shown by thefollowing formula (P1). In the formula (P1), n is an integerof preferably not less than 1 and not more than 50, morepreferably not less than 1 and not more than 20, furtherpreferably not less than 2 and not more than 10.

[0026]

[0027] One end of the structure of the PEG linker site may bemodified by a structure derived from a commercially availablePEGylation reagent or a structure derived from a reagentgenerally used for PEGylation. Although not particularlylimited, examples thereof include structures derived fromdiglycolic acid or a derivative thereof, and maleimide or aderivative thereof.

[0028] In the present step, as the combination of the atomicgroups capable of click reaction, an appropriate combination isselected according to the type of the click reaction. Forexample, a combination of alkyne and azide, a combination of1,2,4,5-tetrazine and alkene, and the like can be mentioned.In these atomic groups, it is sufficient if the first atomicgroup has one of the above-mentioned atomic groups and thesecond atomic group has an atomic group to be a combinationwith the first atomic group. To achieve both the stability ofradioactive metal complex and peptide-modified antibody and theimprovement of the binding efficiency thereof, the first atomicgroup is preferably alkyne and the second atomic group ispreferably azide, or the first atomic group is preferably1,2,4,5-tetrazine and the second atomic group is preferablyalkene. Specific examples of the click reaction by suchcombinations of atomic groups include a Husgen cyclizationaddition reaction, an inverse electron-requested Diels-Alderreaction, and the like.

[0029] Specific examples of the combination of the atomic groupscapable of click reaction include, as shown in the followingformulas, a combination of an atomic group containingdibenzylcyclooctyne (DBCO) as alkyne of the first atomic group(the formula (1a)) and an atomic group containing an azidegroup as azide of the second atomic group (the formula (2a)),or else a combination of an atomic group containing 1,2,4,5-tetrazine as the first atomic group (the formula (1b)) and anatomic group containing trans-cyclooctene (TCO) as alkene ofthe second atomic group (the formula (2b)).

[0030]

[0031] (in the formula (1a), R1 is a binding site with a modified siteor a chelate site, and in the formula (2a), R2 is a peptidebinding site of the peptide-modified antibody.)

[0032]

[0033] (in the formula (1b), one of R3 and R4 is a binding site withother structure, and the other is a hydrogen atom, a methylgroup, a phenyl group or a pyridyl group, and in the formula(2b), R5 is a binding site with other structure.)

[0034] In this step, when the radioactive metal complex and thepeptide-modified antibody are capable of click reaction, theorder of addition of these does not matter. For example, oneof the radioactive metal complex and the peptide-modifiedantibody is added to a reaction container containing a solvent,and then the other is added to perform the reaction, or one ofthe radioactive metal complex and the peptide-modified antibodyis dispersed in a solvent and the other is added to thedispersion to perform the reaction. Alternatively, these maybe simultaneously added to a reaction container containing asolvent to perform the reaction.

[0035] As the solvent to be used in this step, solventscontaining water can be used. For example, water, saline, orbuffer such as sodium acetate buffer, ammonium acetate buffer,phosphate buffer, phosphate buffered saline, trishydroxymethylaminomethane buffer (hereinafter to be simplyreferred to as "Tris buffer"), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer (hereinafter to be simplyreferred to as "HEPES buffer"), tetramethylammonium acetatebuffer or the like can be used. When a buffer is used, inorder to simultaneously achieve both the stability of complexand antibody, and the binding efficiency thereof, the lowerlimit of pH at 25°C is preferably not less than 3.5, morepreferably not less than 4.0, further preferably not less than4.5, further more preferably not less than 5.0, particularlypreferably not less than 5.5, the upper limit is preferably notmore than 10.0, more preferably not more than 9.5, furtherpreferably not more than 9.0, further more preferably not morethan 8.5, particularly preferably not more than 8.0, and apreferable range is not less than 4.0 and not more than 10.0,more preferably not less than 5.5 and not more than 8.5.

[0036] In order to enhance the binding efficiency between aradioactive metal complex and a peptide-modified antibody whileavoiding unintended denaturation of the peptide-modifiedantibody, the upper limit of the reaction temperature of theclick reaction in this step is preferably not more than 120°C,more preferably not more than 90°C, further preferably not morethan 50°C, further more preferably not more than 40°C. Thelower limit of the reaction temperature is not particularlylimited as long as it is a temperature at which the clickreaction can be performed. It is preferably not less than 10°C,more preferably not less than 15°C, further preferably not lessthan 20°C, further more preferably not less than 30°C,particularly preferably not less than 35°C. On the conditionthat the aforementioned reaction temperature applies, the lowerlimit of the reaction time of the click reaction is preferablynot less than 5 min, more preferably not less than 10 min,further preferably not less than 20 min, further morepreferably not less than 30 min, particularly preferably notless than 60 min, and the upper limit is preferably not morethan 36 hr, more preferably not more than 24 hr, further morepreferably not more than 20 hr, particularly preferably notmore than 15 hr, and a preferable range is not less than 5 minand not more than 24 hr, more preferably not less than 10 minand not more than 20 hr.

[0037] The amount of the reaction solution is not particularlylimited. From the aspect of practicality in the productionstep, the lower limit is preferably not less than 0.01 mL, morepreferably not less than 0.1 mL, further preferably not lessthan 1 mL, and the upper limit is preferably not more than 1000mL, more preferably not more than 100 mL, further preferablynot more than 10 mL, both at the start of this step. Forexample, it is preferably not less than 0.1 mL and not morethan 10 mL. In addition, the concentrations of the radioactivemetal complex and the peptide-modified antibody in the reactionsolution are each independently preferably not less than 0.01μmol / L, more preferably not less than 0.1 μmol / L, furtherpreferably not less than 1 μmol / L as the lower limit, andpreferably not more than 10000 μmol / L, more preferably not morethan 1000 μmol / L, further preferably not more than 100 μmol / L,as the upper limit, both at the start of this step. Forexample, it is preferably not less than 1 μmol / L and not morethan 100 μmol / L, from the aspect of the yield of the desiredradioactive metal-labeled antibody.

[0038] The obtained radioactive metal-labeled antibody may beused as it is, or may be purified by using a filtration filter,a membrane filter, a column packed with various fillers,chromatography or the like.

[0039] According to the production method of the presentinvention including the aforementioned steps, a radioactivemetal complex and a peptide-modified antibody are bonded undermild reaction conditions to obtain a radioactive metal-labeledantibody in a high yield. Since the obtained labeled antibodycan be specifically labeled at a site that does not inhibit theantigen specificity of the antibody, the antigen specificity ofthe antibody itself is maintained. In particular, in theabove-mentioned step, the binding reaction between theradioactive metal complex and the peptide-modified antibody canproceed sufficiently and in a short time without performing aheat treatment for promoting the binding reaction between thecomplex and the antibody. Therefore, even when a radioactivemetal having a short half-life such as a positron-emittingnuclide is used, a labeled antibody having high radiochemicalpurity and high radiochemical yield can be obtained in a shorttime.

[0040] The production method of the present invention preferablyincludes a step (complex formation step) of reacting the ligandwith the radioactive metal to form a radioactive metal complexbefore the labeling step, so that the radioactive metal used forlabeling can be used according to the use and object of thelabeled antibody without particular limitation. The ligandused in this step preferably has a first atomic group. Inaddition, from the aspect of increasing the complex formationefficiency, the radioactive metal in this step is preferablyused in the form of an ionizable radioactive metal compound,further preferably in the form of a radioactive metal ion(hereinafter, these embodiments are collectively referred to asa "radioactive metal source").

[0041] From the aspect of increasing the formation efficiency ofthe radioactive metal complex without depending on thecombination of the ligand and the radioactive metal, it ispreferable to heat and react the ligand and the radioactivemetal in the complex formation step. The complex formation maynot proceed well under non-heating conditions, depending on thecombination of the ligand and the radioactive metal. However, byforming under heating conditions a complex with a radioactivemetal ion coordinated therein, the complex formation can beefficiently performed without depending on the combination ofthe ligand and the radioactive metal.

[0042] In the complex formation step, when a complex with aradioactive metal ion can be formed, the order of addition ofthe ligand and the radioactive metal source does not matter.For example, one of the ligand and the radioactive metal sourceis added to a reaction container containing a solvent, and thenthe other is added to perform the reaction, or one of theligand and the radioactive metal source is dispersed in asolvent and the other is added to the dispersion to perform thereaction. Alternatively, these may be simultaneously added toa reaction container containing a solvent to perform thereaction.

[0043] As the reaction conditions in the complex formation step,for example, the following conditions can be adopted. As thesolvent to be used in this step, water, saline, or a buffersuch as sodium acetate buffer, ammonium acetate buffer,phosphate buffer, phosphate buffered saline, Tris buffer, HEPESbuffer, or tetramethylammonium acetate buffer, or a water-soluble organic solvent such as alcohol with a carbon number ofnot less than one and not more than 5, acetonitrile, N,Ndimethylformamide,tetrahydrofuran, dimethyl sulfoxide, acetoneor the like, or a mixed solvent thereof can be used. Thereaction temperature may be, for example, room temperature(25°C) or under heating conditions. In order to simultaneouslysuppress decomposition of the ligand and improve the formationefficiency of the complex, the upper limit is preferably notmore than 120°C, more preferably not more than 90°C, furtherpreferably not more than 50°C, more preferably not more than40°C. The lower limit is not particularly limited as long asit is a temperature at which the click reaction can beperformed. It is preferably not less than 0°C, more preferablynot less than 10°C, further preferably not less than 15°C,further more preferably not less than 20°C, still more furtherpreferably not less than 30°C, particularly preferably not lessthan 35°C. Heating is performed at preferably not less than30°C and not more than 100°C, further preferably not less than37°C and not more than 90°C. On the condition that theaforementioned reaction temperature applies, the lower limit ofthe reaction time is preferably not less than 5 min, morepreferably not less than 10 min, further preferably not lessthan 20 min, further more preferably not less than 30 min,particularly preferably not less than 60 min, and the upperlimit is preferably not more than 300 min, more preferably notmore than 150 min, further preferably not more than 120 min,particularly preferably not more than 60 min. It is preferablynot less than 10 min and not more than 150 min, furtherpreferably not less than 30 min and not more than 60 min.

[0044] As the radioactive metal source in the complex formationstep, for example, a solution of a radioactive metal iondispersed or dissolved in a solvent mainly containing water canbe used.

[0045] The amount of the reaction solution is not particularlylimited. From the aspect of practicality in the productionstep, the lower limit is preferably not less than 0.01 mL, morepreferably not less than 0.1 mL, further preferably not lessthan 1 mL, and the upper limit is preferably not more than 1000mL, more preferably not more than 100 mL, further preferablynot more than 10 mL, both at the start of this step. Forexample, it is preferably not less than 0.01 mL and not morethan 100 mL. In addition, the concentrations of the ligand andthe radioactive metal ion in the reaction solution are eachindependently preferably not less than 0.01 μmol / L, morepreferably not less than 0.1 μmol / L, further preferably notless than 1 μmol / L as the lower limit, and preferably not morethan 10000 μmol / L, more preferably not more than 1000 μmol / L,further preferably not more than 100 μmol / L, as the upper limit,both at the start of this step. For example, it is preferablynot less than 1 μmol / L and not more than 100 μmol / L, from theaspect of the yield of the desired radioactive metal complex.The molar ratios of the ligand and the radioactive metal ionvary depending on the kind of the ligand and radioactive metalion to be used. As the ligand / radioactive metal ion, the lowerlimit is preferably not less than 10 / 1, more preferably notless than 100 / 1, not less than 200 / 1, further preferably notless than 300 / 1, further more preferably not less than 500 / 1,and the upper limit is preferably not more than 10000 / 1, morepreferably not more than 9000 / 1, further preferably not morethan 8000 / 1, further more preferably not more than 7000 / 1. Itis preferably within the range of not less than 200 / 1 and notmore than 10000 / 1, particularly preferably not less than 500 / 1and not more than 7000 / 1.

[0046] The obtained radioactive metal complex may be used as itis, or may be purified by using a filtration filter, a membranefilter, a column packed with various fillers, chromatography orthe like. In particular, in this step, even when low-energyradiation which is difficult to detect or a radioactive metalnuclide that emits α-ray is used, complex formation proceedswell and the yield of the resultant product is high. Thus, acomplex containing the radioactive metal nuclide can beadvantageously subjected to the subsequent steps in anunpurified state.

[0047] From the aspects of improving the reaction efficiency ofthe reaction between the ligand and the radioactive metal ion,and improving the reaction efficiency of the click reactionbetween the obtained complex and the peptide-modified antibody,it is preferable that the ligand has a chelate site where aradioactive metal ion is coordinated and a modified site bondedto the first atomic group.

[0048] As shown by the following formula (3a), the modified site(Rm in the formula (3a)) is bonded to the aforementionedchelate site (Ch in the formula (3a)), and also bonded to theaforementioned first atomic group (AG in the formula (3a)). Inthe formula (3a), Rm is a straight chain or branched chain,substituted or unsubstituted atomic group having a total carbonatom number of not less than 10 and not more than 50.

[0049]

[0050] The modified site Rm is not particularly limited in thebinding mode with the chelate site Ch as long as the complex canbe formed between the ligand and the radioactive metal ion. Fromthe aspect of efficiently forming a complex between the ligandand the radioactive metal ion, it is preferable that themodified site Rm and the chelate site Ch form a thiourea bondand bind to each other, or the modified site Rm and the chelatesite Ch form an amide bond and bind to each other. From theaspect of increasing the labeling efficiency of the radioactivemetal complex and the antibody, the modified site Rm is alsopreferably bound to R1, and R3 or R4 represented by the abovementionedformulas (1a) and (1b) in the first atomic group.

[0051] From the aspect of further increasing the labelingefficiency of the radioactive metal complex and the antibody, itis preferable that a structure represented by the followingformula (P2) is bonded to the modified site of a structurerepresented by Rm in the formula (3a). The structure of theformula (P2) is derived from ethylene glycol, and in the formula(P2), r is preferably an integer of not less than 2 and not morethan 50, further preferably not less than 2 and not more than30.

[0052]

[0053] The chelate site is not particularly limited as long asit has, in the structure thereof, a site where radioactivemetal is coordinated. It is preferably represented by CB25TE2A(1,4,8,11-Tetraazabicyclo[6.6.2]hexadecane-4,11-diaceticacid), CDTA(Cyclohexane-trans-1,2-diamine tetra-acetic acid),CDTPA(4-cyano-4-[[(dodecylthio)thioxomethyl]thio]-Pentanoicacid), DOTA(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraaceticacid), DOTMA((1R,4R,7R,10R)-α,α',α'',α'''-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid),DOTAM(1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane), DOTA-GA(α-(2-Carboxyethyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid),DOTP(((1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(methylene))tetraphosphonic acid),DOTMP(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrakis(methylenephosphonic acid)), DOTA-4AMP(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamidomethylenephosphonic acid),D02P(Tetraazacyclododecane dimethanephosphonic acid),Deferoxamine (DFO), DTPA(Glycine, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-), DTPA-BMA(5,8-Bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oic acid), EDTA(2,2',2'',2'''-(ethane-1,2-diylbis(azanetriyl))tetraacetic acid), NOTA(1,4,7-Triazacyclononane-1,4,7-triacetic acid), NOTP(1,4,7-Triazacyclononane-1,4,7-triyltris(methylenephosphonic acid),TETPA(1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionicacid), TETA(1,4,8,11-Tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid), TTHA(3,6,9,12-Tetrakis(carboxymethyl)-3,6,9,12-tetraazatetradecanedioic acid), HEHA(1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid), 1,2-HOPO(N,N',N'',N'''-tetra(1,2-dihydro-1-hydroxy-2-oxopyridine-6-carbonyl)-1,5,10,14-tetraazatetradecane), PEPA(1,4,7,10,13-pentaazacyclopentadecane-N,N',N'',N''',N''''-penta-acetic acid),H4octapa(N,N'-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N'-diacetic acid), H2bispa2(6,6'-({9-hydroxy-1,5-bis(methoxycarbonyl)-2,4-di(pyridin-2-yl)-3,7-diazabicyclo[3.3.1]nonane-3,7-diyl}bis(-methylene))dipicolinicacid), H2dedpa(1,2-[{6-(carboxy)-pyridin-2-yl}-methylamino]ethane), H2macropa(6-(1,4,10,13-tetraoxa-7,16-diazacyclooctadecan-N,N'-methyl)picolinic acid),H5decapa(N,N''-bis(6-carboxy-2-pyridylmethyl)-diethylenetriamine-N,N',N''-triacetic acid), H6phospa(N,N'-(methylenephosphonate)-N,N'-[6-(methoxycarbonyl)pyridin-2-yl]-methyl-1,2-diaminoethane), HP35D03A(Hydroxypropyltetraazacyclododecanetriacetic acid), orporphyrin, or any one of the following formulas (A) to (K).These structures can be appropriately selected according to thekind of the radioactive metal described later. The effect ofthe present invention is sufficiently achieved using anychelate site.

[0054]

[0055]

[0056] In the formula (A), R11, R13 and R14 are each independentlya group consisting of -(CH2)pCOOH, -(CH2)pC5H5N, -(CH2)pPO3H2, -(CH2)pCONH2 or -(CHCOOH)(CH2)pCOOH, one of R12 and R15 is ahydrogen atom, a carboxyl group, or a carboxyalkyl group having2 or 3 carbon atoms, the other is a group bonded to the abovementionedmodified site, and p is an integer of not less than 0and not more than 3.

[0057] In the formula (B), R21, R22, R23 and R24 are eachindependently a carboxyl group or a carboxyalkyl group having acarbon number of 2 or 3, and any one group of R21, R22, R23 orR24 is bonded to the above-mentioned modified site.

[0058] In the formula (C), R31, R32, R33 and R34 are eachindependently a group composed of an atomic group having ahydrogen atom and not less than 2 and not more than 10 carbonatoms, and optionally containing a nitrogen atom or an oxygenatom, and R35 is a group bonded to the above-mentioned modifiedsite.

[0059] In the formula (D), one of R41 and R42 is a group composedof an atomic group having a hydrogen atom and not less than 5and not more than 20 carbon atoms and containing one or morekinds selected from nitrogen atom, oxygen atom and sulfur atom,and the other is a group bonded to the above-mentioned modifiedsite.

[0060] In the formula (E), R51, R52, R53, R54 and R55 are eachindependently a carboxyl group, or a carboxyalkyl group havinga carbon atom number of 2 or 3, and any one group of R51, R52,R53, R54 or R55 is bonded to the above-mentioned modified site.

[0061] In the formula (F), R61, R62, R63, R64, R65 and R66 are eachindependently a carboxyl group, or carboxyalkyl group having acarbon atom number of 2 or 3, and R67 is a group bonded to theabove-mentioned modified site.

[0062] In the formula (G), R71 and R72 are -O(CH2CH2O)nCH3 (n isan integer of not less than 1 and not more than 5), R73, R75, R76and R78 are each independently an alkyl group having a carbonatom number of not less than 1 and not more than 5, one of R74and R77 is a hydroxyalkyl group having a carbon number of notless than 1 and not more than 5, and the other is a groupbonded to the above-mentioned modified site.

[0063] In the formula (H), R81 and R82 are each independently analkyl group having a carbon number of not less than 1 and notmore than 5, a terminal of the alkyl group may be substitutedby a pyridyl group substituted by one or more carboxyl groups,R87 is -CHOH or -C=O, any one group of R81, R82 or R87 is a groupbonded to the above-mentioned modified site, R83 and R84 areoptionally substituted pyridinyl groups, R85 and R86 are eachindependently -COORa, and Ra is an alkyl group having a carbonnumber of not less than 1 and not more than 5.

[0064] In the formula (I), R91, R92, R93 and R94 are eachindependently -OCH2COOH, any one group of R91, R92, R93 or R94 isa group bonded to the above-mentioned modified site, and R95,R96, R97 and R98 are each independently an alkyl group having acarbon number of not less than 1 and not more than 6.

[0065] In the formula (J), R101, R102 and R103 are eachindependently a carboxyl group or a carboxyalkyl group having acarbon atom number of 2 or 3, or at least one of R101, R102 andR103 in the formula (J) is a group bonded to the above-mentionedmodified site and the other group is a carboxyl group, or acarboxyalkyl group having a carbon atom number of 2 or 3.

[0066] In the above-mentioned formulas (A) to (J), the "groupbonded to the modified site" is a structure derived from acarboxyl group, an amino group, an N-hydroxysuccinimidoester(NHS) group, a 2,6-dioxotetrahydro-2H-pyranyl group, anisocyanate group, or a structure of an isothiocyanate groupbonded to a modified site.

[0067] Examples of the specific structure represented by theformula (A) include structures derived from the compoundsrepresented by the following formulas (A-1) to (A-12).

[0068]

[0069]

[0070]

[0071] Examples of the specific structure represented by theformula (B) or (C) include structures derived from a compoundrepresented by the following formulas (B-1) to (B-2) or (C-1)to (C-5).

[0072]

[0073]

[0074] Examples of the specific structure represented by theformula (D) or (E) include structures derived from a compoundrepresented by the following formulas (D-1) to (D-3), or (E-1).

[0075]

[0076] Examples of the specific structure represented by theformula (F) or (G) include structures derived from a compoundrepresented by the following formulas (F-1) to (F-2) or (G-1).

[0077]

[0078] Examples of the specific structure represented by theformula (H) or (I) include structures derived from a compoundrepresented by the following formulas (H-1) to (H-4), or (I-1).

[0079]

[0080]

[0081] Examples of the specific structure represented by theformula (J) include structures derived from a compoundrepresented by the following formulas (J-1) to (J-5).

[0082]

[0083] The binding site between the chelate site and themodified site is preferably an amide bond or a thiourea bond asmentioned above, more preferably an amide bond from the aspectof yield.

[0084] The amide bond can be formed, for example, by thereaction of a carboxyl group of the compound of the abovementionedformula (B-1) to (B-2), (G-1), (H-1) to (H-4), (I-1),(J-1) to (J-3), an N-hydroxysuccinimidoester (NHS) group of theabove-mentioned formula (A-10) or (A-11), or a 2,6-dioxotetrahydro-2H-pyranyl group of the above-mentioned (A-12), withprimary amine. Alternatively, the amide bond can be formed,for example, by the reaction of an amino group at the right endof the compound represented by the formula (K), and a reagenthaving a hydroxy group, a carboxyl group, or an NHS group.When a reagent having a hydroxy group is reacted, the hydroxygroup is converted to a carboxyl group before use. Thethiourea bond can be formed by the reaction of anisothiocyanate group of the compound of the above-mentionedformula (A-2), (A-3), (D-2), or (F-2), with primary amine or amaleimide group.

[0085] The modified site can be formed by variously selectingfrom commercially available reagents containing a primary amineor commercially available reagents capable of forming an amidebond or a thiourea bond, to all of which a desired first atomicgroup is bonded.As such a reagent, when Dibenzylclocityne (DBCO)represented by the above-mentioned formula (1a) is used as thefirst atomic group, DBCO-amine, DBCO―maleimide, DBCO-PEG-NHSester, DBCO-PEG-alcohol, DBCO-PEG-amine, DBCO-PEG-maleimide andthe like, preferably DBCO-amine, DBCO―maleimide, DBCO-PEG-amine,DBCO-PEG-maleimide, can be selected.

[0086] The radioactive metal complex is not particularly limitedas long as it is formed by reacting a radioactive metal with aligand having a structure composed of those appropriatelyselected from the aforementioned first atomic group, a chelatesite and a modified site. The radioactive metal complex ispreferably formed by reacting a ligand having a structurerepresented by the following formula (ii) with a radioactivemetal.A-B-C...(ii)In the formula (ii), A is a chelate site represented bythe following formula (iia).

[0087]

[0088] In the formula (iia), Ra, Rb and Rc are eachindependently a group consisting of -(CH2)pCOOH, -(CH2)pC5H5N, -(CH2)pPO3H2, -(CH2)pCONH2 or -(CHCOOH)(CH2)pCOOH, p is an integerof not less than 0 and not more than 3, one of Rd and Re is abinding site (*) with B, and other is a hydrogen atom or agroup consisting of -(CH2)pCOOH, -(CH2)pC5H5N, -(CH2)pPO3H2, -(CH2)pCONH2 or, -(CHCOOH)(CH2)pCOOH, and p is an integer of notless than 0 and not more than 3.In the formula (ii), B is represented by the followingformula (iib).

[0089]

[0090] In the formula (iib), La and Lb are each independently abond linker containing at least an amide bond or a thioureabond and not less than 1 and not more than 50 carbon atoms, tis an integer of not less than 0 and not more than 30, s is 0or 1, * is a binding site with A, and ** is a binding site withC.

[0091] In the formula (ii), C is either an alkyne derivativerepresented by the following formula (iic) or a tetrazinederivative represented by the formula (iid).

[0092]

[0093] In the formula (iic), X is CHRk―** or N-**, Y is CHRk orC=O, Rk is independently a hydrogen atom or an alkyl grouphaving not less than 1 and not more than 5 carbon atoms, when Xis CHRk―** and Y is CHRk, then Rk moieties may be joined toform a cycloalkyl group, Rf, Rg, Rh and Ri are eachindependently a hydrogen atom, a halogen atom, or an alkylgroup having not less than 1 and not more than 5 carbon atoms,Rf and Rg may be joined, or Rh and Ri may be joined to form ahydrocarbocycle, ** is a binding site with B, in the formula(iid), ** is a binding site with B, and Rj is a hydrogen atom,a methyl group, a phenyl group or a pyridyl group.

[0094] As the ligand for A, a DOTA derivative of the abovementionedformula (iia) wherein Ra to Rd are -(CH2)pCOOH, p is1, Re is a binding site with B; or DO3A derivative or DOTAGAderivative wherein Ra to Rc are -(CH2)pCOOH, p is 1, Rd is abinding site (*) with B, and Re is a hydrogen atom is morepreferred.

[0095] In the formula (ii), a DOTA-PEGt-DBCO derivative whereinA is the above-mentioned DOTA derivative, in B, La is a bondlinker containing a thiourea bond and having not less than 1and not more than 50 carbon atoms, s is 0 or 1, when s is 1, tis an integer of not less than 0 and not more than 30, Lb is abond linker containing an amide bond or a thiourea bond andhaving not less than 1 and not more than 50 carbon atoms, and Cis an alkyne derivative represented by the formula (iic),wherein, in the formula (iic), X is N―**, Y is CHRk, Rk is ahydrogen atom, Rf and Rg are jointed to form a benzene ring, Rhand Ri are jointed to form a benzene ring, and ** is a bindingsite with B; or a DOTA-PEGt-Tz derivative wherein, in B, La isa bond linker containing a thiourea bond and having not lessthan 1 and not more than 50 carbon atoms, s is 0 or 1, when sis 1, t is an integer of not less than 0 and not more than 30,Lb is a bond linker containing an amide bond or a thiourea bondand having not less than 1 and not more than 50 carbon atoms,and C is a tetrazine derivative represented by the formula(iid), is further more preferred.

[0096] In the formula (ii), a DO3A-PEGt-DBCO derivative whereinA is the above-mentioned DO3A derivative, in B, La is a bondlinker containing an amide bond or a thiourea bond and havingnot less than 1 and not more than 50 carbon atoms, s is 0 or 1,when s is 1, t is an integer of not less than 0 and not morethan 30, Lb is a bond linker containing an amide bond or athiourea bond and having not less than 1 and not more than 50carbon atoms, and C is an alkyne derivative represented by theformula (iic), wherein, in the formula (iic), X is N―**, Y isCHRk, Rk is a hydrogen atom, Rf and Rg are jointed to form abenzene ring, Rh and Ri are jointed to form a benzene ring, and** is a binding site with B is further more preferred.

[0097] In the formula (ii), a DOTAGA-PEGt-DBCO derivativewherein A is the above-mentioned DOTAGA derivative, in B, La isa bond linker containing an amide bond or a thiourea bond andhaving not less than 1 and not more than 50 carbon atoms, s is0 or 1, when s is 1, t is an integer of not less than 0 and notmore than 30, Lb is a bond linker containing an amide bond or athiourea bond and having not less than 1 and not more than 50carbon atoms, and C is an alkyne derivative represented by theformula (iic), wherein, in the formula (iic), X is N―**, Y isCHRk, Rk is a hydrogen atom, Rf and Rg are jointed to form abenzene ring, Rh and Ri are jointed to form a benzene ring, and** is a binding site with B is further more preferred.

[0098] The matters applicable in common to each of theaforementioned embodiments are described below. In thepeptide-modified antibody used in the present invention, aspecific site of the antibody is specifically modified by thepeptide, preferably the Fc region (constant region) of theantibody is specifically modified, and particularly preferablythe lysine residue in the Fc region of the antibody is modifiedsite-specifically. That is, in the present invention, a stepof reacting a peptide with an antibody to obtain a peptidemodifiedantibody (antibody modification step) may be providedprior to the labeling step.

[0099] The antibody used in the present invention may be apolypeptide containing an Fc region, and may be a monoclonalantibody or a polyclonal antibody. A monoclonal antibody ispreferred. Monoclonal antibody also includes artificiallymodifiedgenetically-modified antibodies such as antibodyvariants (chimeric antibody, humanized antibody, etc.).

[0100] The peptide used in the present invention may be a chainpeptide or a cyclic peptide as long as it modifies the Fcregion of the antibody in a site-specific manner, and a cyclicpeptide is preferred. It preferably includes an amino acidsequence consisting of 13 to 17 amino acid residues representedby the following formula (i). In the following description ofthe amino acid sequence, the left side of the page of the aminoacid sequence indicates the N-terminal side, and the right sideof the page of the amino acid sequence indicates the C-terminalside. The binding position of the second atomic group linkedto the peptide is not particularly limited as long as a clickreaction can occur with the first atomic group. From theaspect of improving reactivity, the N-terminal or C-terminal ofthe peptide preferably has a second atomic group, and the N-terminal of the peptide more preferably has a second atomicgroup.

[0101] (Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd) ··· (i)In the above-mentioned formula (i), Xa, Xb, Xc and Xd arecontinuous X in the number of a, continuous X in the number ofb, continuous X in the number of c, and continuous X in thenumber of d, respectively,X is an amino acid residue having neither a thiol group nor ahaloacetyl group in the side chain,a, b, c and d are each independently an integer of not lessthan one and not more than 5, and satisfy a+b+c+d14,Xaa1 and Xaa3 are each independently an amino acid residuederived from an amino acid having a thiol group in the sidechain, and they are bonded via a disulfide bond or theirsulfide groups are bonded via a linker, orone is an amino acid residue derived from an amino acid havinga thiol group in the side chain and the other is an amino acidresidue derived from an amino acid having a haloacetyl group inthe side chain, and they are bonded via a thioether bond, andXaa2 is a lysine residue, arginine residue, cysteine residue,aspartic acid residue, glutamic acid residue, 2-aminosubericacid, or diamino propionic acid, and preferably modified with acrosslinking agent.

[0102] Examples of the amino acid residue that may be containedin X in the above-mentioned formula (i) include those derivedfrom amino acids such as glycine, alanine, phenylalanine,proline, asparagine, aspartic acid, glutamic acid, arginine,histidine, serine, threonine, tyrosine, methionine and the like,and X may be an amino acid residue consisting of the same typeof amino acid, or different types of amino acids.

[0103] The numbers a, b, c and d in the formula (i) are notparticularly limited as long as they are within theaforementioned range. From the aspect of binding stabilitybetween the peptide and the antibody, a+b+c+d≤14 being thecondition wherein a is preferably an integer of not less than 1and not more than 3, b is preferably an integer of not lessthan 1 and not more than 3, c is preferably an integer of notless than 3 and not more than 5, and d is preferably an integerof not less than 1 and not more than 3.

[0104] Xaa1 and Xaa3 are amino acid residues derived from anamino acid having a thiol group in the side chain, and may bethe same or different. Examples of the amino acid having athiol group in the side chain include cysteine and homocysteine.Such amino acid residues are preferably bonded by a disulfidebond, or a sulfide group is preferably bonded thereto via alinker shown by the following formula (4). In the formula (4),the broken line indicates the binding part with the sulfidegroup.

[0105]

[0106] Instead of the aforementioned combination of Xaa1 andXaa3, one of Xaa1 and Xaa3 may be an amino acid residue derivedfrom an amino acid having a thiol group in the side chain, andthe other may be an amino acid residue derived from an aminoacid having a haloacetyl group in the side chain. These arebonded via a thioether bond. The terminal of the haloacetylgroup is substituted with a halogen such as iodine or the like,and the halogen is eliminated by a reaction with the thiolgroup in the other side chain, whereby a thioether bond isformed.

[0107] A specific amino acid sequence of the peptide representedby the formula (i) is, for example, the peptide described in WO2016 / 186206, WO 2017 / 217347 or WO 2018 / 230257, and these canalso be used.

[0108] Among these, the amino acid sequence of the peptidepreferably has any one of the following sequences (1)-(14),more preferably the following sequence (1), (2), (13) or (14).The presence of such amino acid sequence can enhance thebinding affinity between the peptide and the antibody (e.g.,human IgG). In the following amino acid sequences (1)-(14),(Xaa2) is a lysine residue, a cysteine residue, an asparticacid residue, a glutamic acid residue, a 2-aminosuberic acid,or a diamino propionic acid, and is preferably modified by acrosslinking agent. (Xaa1) and (Xaa3) both show homocysteineresidues. In the following amino acid sequences (1)-(14), theamino acids other than (Xaa1), (Xaa2) and (Xaa3) are indicatedby one-letter abbreviations.

[0109] (1) DCAYH(Xaa2)GELVWCT(2) GPDCAYH(Xaa2)GELVWCTFH(3) RCAYH(Xaa2)GELVWCS(4) GPRCAYH(Xaa2)GELVWCSFH(5) SPDCAYH(Xaa2)GELVWCTFH(6) GDDCAYH(Xaa2)GELVWCTFH(7) GPSCAYH(Xaa2)GELVWCTFH(8) GPDCAYH(Xaa2)GELVWCSFH(9) GPDCAYH(Xaa2)GELVWCTHH(10) GPDCAYH(Xaa2)GELVWCTFY(11) SPDCAYH(Xaa2)GELVWCTFY(12) SDDCAYH(Xaa2)GELVWCTFY(13) RGNCAYH(Xaa2)GQLVWCTYH(14) G(Xaa1)DCAYH(Xaa2)GELVWCT(Xaa3)H

[0110] The peptide to be used in the present invention can beproduced using a combination of amino acids regardless ofnatural amino acids and unnatural amino acids, by subjecting topeptide synthesis methods such as liquid phase synthesisprocess, solid phase synthesis process, automatic peptidesynthesis method, gene recombinant method, phage display methodor the like. In the synthesis of the peptide, where necessary,the functional groups of the amino acids to be used may beprotected. These methods can be performed according to themethod described in, for example, WO 2017 / 217347 and WO2018 / 230257.

[0111] As a method for introducing the aforementioned secondatomic group into peptide in the present invention, anintroduction method including obtaining a peptide having adesired amino acid sequence by the aforementioned method,dissolving the peptide in a solution containing a solubilizingagent and a reducing agent and where necessary, an acid, addingan organic solvent solution of an atomic group containing anazide group or TCO as the second atomic group to the solution,and stirring the mixture at room temperature can be mentioned.

[0112] When an atomic group containing an azide group isintroduced as the second atomic group, the azide group isdirectly introduced into the N-terminal or C-terminal of apeptide by using a commercially available azide groupintroducingreagent according to a conventional method, or anatomic group containing an azide group can be introduced viathe aforementioned linker structure. Examples of the azidegroup-introducing reagent to be used include silyl azide, azidephosphate, alkyl ammonium azide, inorganic azide, sulfonylazide, PEG azide, and the like.

[0113] When an atomic group containing TCO is introduced as thesecond atomic group, TCO is directly introduced into the Nterminalor C-terminal of a peptide by using a commerciallyavailable click chemistry reagent containing TCO according to aconventional method, or an atomic group containing TCO can beintroduced via the aforementioned linker structure.

[0114] The method for binding a peptide to an antibody to obtaina peptide-modified antibody can be performed using, for example,a crosslinking agent. A crosslinking agent is a chemicalsubstance for linking a peptide and an antibody by a covalentbond. Examples thereof include a crosslinking agent preferablycontaining two or more succinimidyl groups such asdisuccinimidyl glutarate (DSG), disuccinimidyl suberate (DSS)and the like, a crosslinking agent consisting of a compoundcontaining two or more imidic acid moieties such as dimethyladipimidate and the like, or a salt thereof, a crosslinkingagent consisting of a compound having a disulfide bond such asdimethyl 3,3'-dithiobispropionimidate,dithiobissuccinimidylpropionic acid, and the like, or a saltthereof, and the like. Using such crosslinking agent, acrosslinking reaction can be caused between an amino acidresidue of Xaa2 in the peptide and an antibody. As the sitewhere the crosslinking reaction occurs in the antibody, whenhuman IgG (e.g., trastuzumab) is used as the antibody, site25specific binding occurs via a crosslinked structure, betweenthe amino acid residue of Xaa2 and at least one of the Lys246residue and the Lys248 residue according to Eu numbering intrastuzumab. These Lys residues are present in the Fc regionof human IgG, and even if the antibody is other thantrastuzumab, those skilled in the art can align the amino acidsequence of the antibody and identify the corresponding Lysresidue.

[0115] The method for binding the peptide to the antibody can beperformed, for example, by dispersing the aforementionedpeptide, an antibody, a crosslinking agent, and a catalyst asnecessary in an appropriate buffer at not less than 10°C andnot more than 30°C. The reaction time may be about not lessthan 10 min to about 2 hr. The molar ratio at the time ofreaction of the peptide and the antibody is preferably withinthe range of 1:1-20:1 as peptide:antibody.

[0116] In the peptide-modified antibody obtained through theabove steps, at least not less than one molecule of a peptidemay be bonded per one molecule of an antibody (preferablyantibody with IgG as the immunoglobulin class). To maintainthe activity of the antibody itself (antigen recognition action,neutralizing action, complement activating action, opsoninaction), a peptide is preferably bonded site-specifically tothe Fc region (constant region) of the antibody. In thepeptide-modified antibody of the present invention, one or twomolecules of the peptide is / are preferably bonded per onemolecule of the antibody.

[0117] The above-mentioned peptide-modified antibody obtainedthrough the above steps is a mixture containing an antibody inwhich one molecule of peptide is bound to one molecule ofantibody (hereinafter referred to as "monovalent antibody") andan antibody in which two molecules of peptide are bound to onemolecule of antibody (hereinafter referred to as "divalentantibody") at any ratio. This may be used as it is for thesubsequent steps, or an unmodified antibody, a monovalentantibody, and a divalent antibody are separated and purified bya method such as filtration filter, membrane filter, columnfilled with various fillers, various chromatographies and thelike, and only the antibody having any valence may be subjectedto the subsequent steps. When the unmodified antibody cannotbe separated from the antibody having other valence as a resultof purification, a mixture containing these may be subjected tothe subsequent steps.When an unmodified antibody, a monovalent antibody, and adivalent antibody are separated and purified, any of the abovementionedpurification methods may be used for separation andpurification. It is preferable to use a column filled withvarious fillers, and it is more preferable to use a columnfilled with a filler suitable for separation and purificationof protein such as antibody and the like.

[0118] As the radioactive metal coordinated in an ionic state tothe radioactive metal complex, a metal nuclide that emits α-ray,β-ray, γ-ray, or a combination thereof can be used. Examplesof such radioactive metal nuclide include alkali metal,alkaline earth metal, lanthanoid, actinide, transition metal,and radioisotope of metals other than these metals. Of these,from the aspect of being commercially available and improvingcomplex formation, 44Sc, 51Cr, 57Co, 58Co, 60Co, 59Fe, 67Ga, 68Ga,64Cu, 67Cu, 89Sr, 89Zr, 90Y, 99mTc, 103Ru, 111In, 153Sm, 165Dy, 166Ho,177Lu, 186Re, 188Re, 198Au, 201Tl, 197Hg, 203Hg, 212Bi, 213Bi, 212Pb,227Th or 225Ac is preferably used as a radioactive metal nuclide.These radioactive metals can be produced according to aconventional method, and are preferably obtained as a solutioncontaining the radioactive metal in an ionized state.

[0119] When the radioactive metal-labeled antibody is used forthe treatment of a disease, α ray-emitting nuclide or β rayemittingnuclide is preferably used as the radioactive metal inorder to enhance the treatment effect. The α ray-emittingnuclide may be any nuclide that emits α ray in the decayprocess of a radioactive metal. Specifically, 212Bi, 213Bi, 227Th,225Ac, or the like is preferably used. More preferred is 227Thor 225Ac, and further preferred is 225Ac. The β ray-emittingnuclide may be any nuclide that emits β ray in the decayprocess of a radioactive metal. In detail, 60Co, 59Fe, 64Cu, 67Cu,89Sr, 90Y, 99mTc, 103Ru, 153Sm, 165Dy, 166Ho, 177Lu, 186Re, 188Re, 198Au,203Hg, 212Bi, 213Bi, 212Pb, and the like are preferably used, and64Cu, 67Cu, 89Sr, 90Y or 177Lu is more preferably used.

[0120] When the radioactive metal-labeled antibody is used forthe diagnosis of disease or detection of lesion, β+ ray-emitting nuclide, electron capture decay nuclide, or γ rayemittingnuclide is preferably used as the radioactive metal inorder to enhance the diagnosis performance. The β+ rayemittingnuclide may be any nuclide that emits positron in thedecay process of a radioactive metal, and 44Sc, 58Co, 68Ga, 64Cu,89Zr, and the like are preferably used, and 64Cu or 89Zr is morepreferred. The electron capture decay nuclide may be anynuclide that emits Auger electron or characteristic X-ray in thedecay process of a radioactive metal, and 51Cr, 57Co, 58Co, 67Ga,68Ga, 64Cu, 89Zr, 111In, 186Re, 201Tl, 197Hg and the like arepreferably used. The γ ray-emitting nuclide may be any nuclidethat emits γ ray by γ decay. As the nuclide that emits γ ray byγ decay, 99mTc, 68Ga or 201Tl is preferably used.

[0121] For example, when a radioactive metal coordinated in anionic state to the radioactive metal complex is selected basedon the ion radius, a radioactive metal with an ion radius ofabout 70-130 pm includes 67Ga, 68Ga, 64Cu, 67Cu, 89Zr, 90Y, 99mTc,103Ru, 111In, 153Sm, 165Dy, 166Ho, 177Lu, 186Re, 188Re, 198Au, 201Tl,197Hg, 203Hg, 212Bi, 213Bi, 212Pb, 225Ac, and the like. These canpreferably form a radioactive metal complex with a ligandhaving a chelate site with a structure represented by theabove-mentioned formulas (A) to (K).

[0122] For example, when the radioactive metal-labeled antibodyis used for the treatment of a disease and 225Ac, 177Lu or 90Y isused as a radioactive metal, it is preferable to use a ligandhaving a chelate site with a structure represented by any of theabove-mentioned formulas (A) or (D) to (I), it is morepreferable to use a ligand having a chelate site with astructure represented by the above-mentioned formula (A), (D)or (F), and it is further preferable to use a ligand having achelate site with a structure represented by the abovementionedformula (A). When the radioactive metal-labeledantibody is used for the diagnosis of disease or detection oflesion and 89Zr or 111In is used as a radioactive metal, it ispreferable to use a ligand having a chelate site with astructure represented by any of the above-mentioned formulas (A),(C) and (K), and it is further preferable to use a ligand havinga chelate site with a structure represented by the above10mentioned formula (A).

[0123] As the immunoglobulin class of the antibody used in thepresent invention, any class of IgG, IgA, IgM, IgD or IgE can beused without particular limitation. Among these, IgG ispreferably used because it is the main class in the secondaryresponse of the immune response, is most abundant in blood, andshows high recognition specificity for antigens. Furthermore,mammalian IgG is preferable, and specific examples of themammal include primates such as human, chimpanzee and the like;experimental animals such as rat, mouse, rabbit and the like;domestic animals such as swine, bovine, horse, sheep, goat andthe like; and pet animals such as dog and cat and the like. Inaddition, human IgG or rabbit IgG is further preferable, andhuman IgG is further more preferable. The subclass of theseantibodies is not particularly limited. For example, whenhuman IgG is used, it may be at least one of IgG1, IgG2, IgG3and IgG4, and IgG1, IgG3 or IgG4 is preferred.

[0124] In the radioactive metal-labeled antibody obtained by theaforementioned production method, a specific site of anantibody is specifically modified with a peptide. Aradioactive metal complex is directly or indirectly linked tothe peptide, and preferably has a binding site-which is formedby a click reaction-between the peptide and the radioactivemetal complex. The binding site is preferably a chemicalstructure derived from the first atomic group that theradioactive metal complex has and the second atomic grouplinked to the peptide. As such chemical structure, for example,the binding site may have a structure containing a substitutedtriazole skeleton or a structure containing a substitutedpyridazine skeleton. As the structure containing theaforementioned substituted skeleton, for example, a structure inwhich a structure containing at least one of a substituent, analiphatic ring and an aromatic ring is bonded to a triazoleskeleton or a pyridazine skeleton, and which has a binding sitewith a modified site or a chelate site and a binding site with apeptide can be mentioned.

[0125] As the structure of a specific binding site, for example,when the first atomic group and the second atomic group are acombination of an atomic group containing DBCO and an atomicgroup containing an azide group, a structure containing atriazole skeleton shown by the following formula (10a) orformula (10b) is formed, depending on the reaction reagent used.Since these are isomers, they may be contained at any ratio.When the first atomic group and the second atomic group are acombination of an atomic group containing 1,2,4,5-tetrazine,and an atomic group containing TCO, a structure containing apyridazine skeleton shown by the following formula (10c) can beformed, depending on the reaction reagent used. In the formula(10a) and the formula (10b), R1A is a binding site with amodified site or a chelate site, R2A is a binding site with apeptide. In the formula (10c), one of R3A and R4A is a hydrogenatom, a methyl group, a phenyl group or a pyridyl group, andthe other is a binding site with a modified site or a chelatesite, and R5A is a binding site with a peptide.

[0126]

[0127] The radioactive metal-labeled antibody may also be usedas it is or after purification for the preparation of aradioactive pharmaceutical composition containing theradioactive metal-labeled antibody as the active ingredient.The radioactive pharmaceutical composition refers to acomposition containing a radioactive metal-labeled antibody ora derivative thereof, and in a form suitable for administrationto a living body. The radioactive pharmaceutical compositioncan be produced, for example, by dissolving a radioactivemetal-labeled antibody produced by the aforementioned method ina solvent mainly composed of water and substantially isotonicwith a living body. In this case, the radioactivepharmaceutical composition is preferably in the form of anaqueous solution, and may contain other pharmaceuticallyacceptable components as necessary. A radioactivepharmaceutical composition is orally or parenterally, forexample, intravenously, subcutaneously, intraperitoneally,intramuscularly, or the like, administered to a living body,and is used for treatment of a disease, diagnosis of a disease,detection of a lesion, or the like.

[0128] Examples of the substituent that can be used tosubstitute the above-mentioned formulas (A) to (J), thetriazole skeleton-containing structure, and the pyridazineskeleton-containing structure include a halogen atom, asaturated or unsaturated alkyl group, a hydroxy group, analdehyde group, a carboxy group, an acyl group, an amino group,a nitro group, an ester group, an isothiocyanate group, athioxy group, a cyano group, an amide group, an imide group, aphosphate group, a phenyl group, a benzyl group, a pyridylgroup, and the like. One of these substituents may be usedalone for substitution, or two or more of these substituents maybe used in combination.EXAMPLE

[0129] The present invention is described in more detail in thefollowing by way of examples. However, the scope of the presentinvention is not limited by the examples. In the Tables below,the column with "-" indicates no performance.

[0130] [Examples 1 to 4](1-1. Complex formation step)The structures of the ligands used in these Examples areshown in the following formulas (L1-1) to (L1-3). DO3A-DBCOrepresented by the formula (L1-1) was synthesized according tothe method described in Liang Y, Jiang X, Yuan R, Zhou Y, Ji C,Yang L et al. Metabolism-Based Click-Mediated Platform forSpecific Imaging and Quantification of Cell Surface SialicAcids. Anal Chem. Jan 3; 89(1): 538-543. (2017). DOTA-DBCOrepresented by the formula (L1-2) was synthesized according tothe method described in Wang H, Wang R, Cai K, He H, Liu Y, YenJ et al. Selective in vivo metabolic cell-labeling-mediatedcancer targeting. Nat Chem Biol. Apr; 13(4): 415-424.(2017).As DO3A-PEG4-DBCO represented by the formula (L1-3), acommercially available product manufactured by Iris BiotechGmbH was used. These ligands were dispersed in 0.1 mol / Lsodium acetate buffer (pH 6.0) as a solvent to give dispersionscontaining 1.7 mmol / L ligand. A reaction mixture of thedispersion (0.0025 mL), and 225Ac ion-containing solution (0.2mol / L aqueous hydrochloric acid solution, radioactivityconcentration 160 MBq / mL, prepared from one produced by OakRidge National Laboratory, liquid amount 0.0025 mL) 0.4 MBq(calculated by attenuation from the amount of radioactivity attest date and time) as a radioactive metal source was reactedunder heating conditions to give a 225Ac complex solution. Themolar ratio of the ligand and the radioactive metal ion wasligand:225Ac ion = 3000:1, and the heating temperature of thereaction mixture was set to 70°C, and the heating time was setto 90 min.

[0131]

[0132] The radiochemical purity of the obtained 225Ac complex wasmeasured by the following method. That is, a part of the 225Accomplex solution was developed by thin layer chromatography(manufactured by Agilent, model number: SGI0001, eluent:acetonitrile / water mixed solution (volume ratio 1:1)), and thenmeasured by radio γ-TLC Analyzer (manufactured by raytest,MODEL GITA Star). The percentage of the radioactivity (count)of the peak detected near the origin with respect to thedetected total radioactivity (count) was defined as theradiochemical purity (%) of the 225Ac complex. As a result, theradiochemical purity of the 225Ac complex was 89-99%. Theobtained 225Ac complex solution was directly used for thelabeling step.

[0133] (1-2. Antibody modification step)Separately, a peptide was produced by the methoddescribed in WO 2017 / 217347 to obtain a peptide containing 17amino acid residues represented by the following formula (P3).The amino acid sequence of this peptide was the same as thesequence in which Xaa2 of SEQ ID NO: (2) was a lysine residue,and the side chain terminal amino group of the lysine residuewas modified with the structure shown by R1. In addition, twocysteine residues form a disulfide bond with each other, and tothe N-terminal of the peptide is added ethyl azide as an atomicgroup containing an azide group, which is the second atomicgroup, via a linker structure having diglycolic acid and eightPEGs.

[0134]

[0135] wherein in the formula (P3), Gly is glycine, Pro is proline,Asp is aspartic acid, Cys is cysteine, Ala is alanine, Tyr istyrosine, His is histidine, Glu is glutamic acid, Leu isleucine, Val is valine, Trp is tryptophan, Phe is phenylalanine.

[0136] A mixture of the peptide and a human IgG antibody(rituximab; manufactured by Roche, or trastuzumab; manufacturedby Roche) in a sodium acetate buffer (pH 6.0) was reacted atroom temperature for 30 min to give a solution containing apeptide-modified antibody. The peptide-modified antibody hasan Fc region of the antibody site-specifically modified by theabove-mentioned peptide.

[0137] (2. Peptide-modified antibody separation step)The aforementioned peptide-modified antibody was dilutedwith 1 mol / L sodium acetate buffer (pH 6.0), added to Protein Acolumn (manufactured by GE Healthcare, HiTrap MabSelect SuRe),and a 0.05 mol / L sodium acetate buffer (pH 5.7) containing 0.15mol / L sodium chloride was flown. A solution containing adivalent antibody was recovered, and the concentration wasadjusted such that the concentration of the divalent antibodycontained in the recovered fraction was 15 mg / mL. Thereafter,0.05 mol / L sodium acetate buffer (pH 3.5) containing 0.15 mol / Lsodium chloride was flown, a solution containing a monovalentantibody was recovered, and the concentration was adjusted suchthat the concentration of the unmodified antibody andmonovalent antibody contained in the recovered fraction was 17-40 mg / mL.

[0138] (3. Labeling step)A solution of the 225Ac complex obtained in each of theaforementioned steps, and a solution containing a peptidemodifiedantibody (monovalent antibody) were each added withoutpurification to 0.02 mol / L ascorbic acid-containing 0.09 mol / Lsodium acetate buffer, and a click reaction was performed at37°C for 120 min to give 225Ac complex-labeled antibodies ofExamples 1 to 4. The amount of the 225Ac complex and the amountof the peptide-modified antibody (monovalent antibody) were 43μmol and 46 μmol (Example 1), respectively, or both 100 μmol(Examples 2 to 4), and the molar ratio of the first atomicgroup (DBCO) and the second atomic group (azide) was about 1:1.The reaction rate (%) of the unpurified 225Ac complex-labeledantibody of the Example is shown in the following Table 1.Here, the reaction rate (%) means the radiochemical purity (%)of the 225Ac complex-labeled antibody with respect to thelabeling rate (%) in the complex formation step, and thelabeling rate (%) means the amount of radioactivity (%) of the225Ac complex with respect to the charged radioactivity amount.Furthermore, a solution of the 225Ac complex-labeledantibody obtained by reacting at 37°C for 2 hr was purifiedusing ultrafiltration filter (manufactured by Merck, modelnumber: UFC505096). The radiochemical purity (RCP) and theradiochemical yield (RCY) of the 225Ac complex-labeled antibodyafter purification are shown in the following Table 1.

[0139] The measurement method of the radiochemical purity andradiochemical yield of the 225Ac complex-labeled antibody was asfollows. That is, thin layer chromatography (manufactured byAgilent, model number: SGI0001, developing solvent was mixedsolution of acetonitrile:0.1 mmol / L EDTA solution (volume ratio1:1)) was measured by radio γ-TLC Analyzer (manufactured byraytest, MODEL GITA Star), and the percentage of theradioactivity (count) of the peak detected near the origin tothe total radioactivity (count) detected was defined as theradiochemical purity (%). In addition, the percentage of theradioactivity (radioactivity level calculated from the countmeasured by γ ray spectrometer (Ge semiconductor detector:GMX10P4-70 (manufactured by ORTEC), Multi Channel Analyzer: M7-000 (manufactured by SEIKO EG&G), data processing: SpectrumNavigator:DS-P300 (manufactured by SEIKO EG&G) and GammaStudio:DS-P600 (manufactured by SEIKO EG&G)) recovered afterultrafiltration purification with respect to the totalradioactivity (similar to the above, the radioactivity levelcalculated from the count measured by γ ray spectrometer) addedat the start of the labeling step was defined as theradiochemical yield (%).

[0140] [Example 5](1-1. Complex formation step)In this Example, a 225Ac complex solution was obtained inthe same manner as in Example 1 except that a ligand with thestructure shown by the following formula (L2) was used. DOTAPEG7-Tz represented by the formula (L2) was synthesizedaccording to the method described in Poty S, Membreno R, GlaserJM, Ragupathi A, Scholz WW, Zeglis BM et al. The inverseelectron-demand Diels-Alder reaction as a new methodology forthe synthesis of 225Ac-labelled radioimmunoconjugates. ChemCommun (Camb). Mar 8; 54(21):2599-2602. (2018).

[0141]

[0142] (1-2. Antibody modification step)The peptide used in this Example was a peptide containing17 amino acid residues represented by the following formula(P4). The amino acid sequence of this peptide was the same asthe sequence in which Xaa2 of SEQ ID NO: (2) was a lysineresidue, and the side chain terminal amino group of the lysineresidue was modified with the structure shown by R2. Inaddition, the thiol groups of the two cysteine residues arelinked to each other by the linker represented by the abovementionedformula (4), and the N-terminal of the peptide had alinker structure including 5 PEGs, a cysteine residuesubstituted by a structure shown by R1, in which residue athiol group of the side chain contains the second atomic groupTCO, two glutamic acid residues, and an acetyl group in thisorder when viewed from the N-terminal side.

[0143]

[0144] wherein in the formula (P4), Gly is glycine, Pro is proline,Asp is aspartic acid, Cys is cysteine, Ala is alanine, Tyr istyrosine, His is histidine, Glu is glutamic acid, Leu isleucine, Val is valine, Trp is tryptophan, Phe is phenylalanine.

[0145] A mixture of the peptide and a human IgG antibody(trastuzumab; manufactured by Roche) in a sodium acetate buffer(pH 6) was reacted at room temperature for 30 min to give asolution containing a peptide-modified antibody.

[0146] (2. Labeling step)A click reaction was performed in the same manner as inExample 1 to give an 225Ac complex-labeled antibody. The amountof the 225Ac complex and the amount of the peptide-modifiedantibody were both 100 μmol, and the molar ratio of the firstatomic group (1,2,4,5-tetrazine) and the second atomic group(TCO) was 1:1. The reaction rate (%) of the unpurified 225Accomplex-labeled antibody of the Example is shown in thefollowing Table 1. Here, the reaction rate (%) means theradiochemical purity (%) of the 225Ac complex-labeled antibodywith respect to the labeling rate (%) in the complex formationstep, and the labeling rate (%) means the amount ofradioactivity (%) of the 225Ac complex with respect to thecharged radioactivity amount. In addition, the radiochemicalpurity (RCP) and the radiochemical yield (RCY) of the 225Accomplex-labeled antibody after purification using anultrafiltration filter in the same manner as in Example 1 areshown in the following Table 1.0147]Table 1]

[0148] As shown in Table 1, it is clear that, in the Examples inwhich the complex and the antibody were reacted after thecomplex formation step, the labeling reaction proceeded undermild reaction conditions without excessive heating of theantibody, and the radioactive metal is superior in the antibodylabeling efficiency.

[0149] [Examples 6 and 7] Production of Tmab, Rmab using 225Ac-labeledDOTAGA-DBCO(1. Complex formation step)The structure of the ligand used in this Example isrepresented by the following formula (L1-4). DOTAGA-DBCOrepresented by the formula (L1-4) was produced based on themethod described in Bernhard et al. DOTAGA-Anhydride: AValuable Building Block for the Preparation of DOTA-LikeChelating Agents Chem. Eur. J. 2012, 18, 7834-7841. Theseligands were dispersed in 0.1 mol / L sodium acetate buffer (pH6.0) as a solvent to give a dispersion containing 1.7 mmol / Lligand. A reaction mixture of the dispersion (0.005 mL), and225Ac ion-containing solution (0.2 mol / L aqueous hydrochloricacid solution, radioactivity concentration 320-340 MBq / mL,prepared from one produced by Oak Ridge National Laboratory,liquid amount: 0.005 mL) 1.6-1.7 MBq (calculated by attenuationfrom the radioactivity level at test date and time) as aradioactive metal source was reacted under heating conditionsto give a 225Ac complex solution. The molar ratio of the ligandand the radioactive metal ion was ligand:225Ac ion = about2500:1, and the heating temperature of the reaction mixture wasset to 70°C, and the heating time was set to 30 min.

[0150]

[0151] The radiochemical purity of the obtained 225Ac complex wasmeasured in the same manner as in Example 1. As a result, theradiochemical purity was 90%. The obtained 225Ac complexsolution was directly used for the next labeling step.

[0152] (2. Labeling step)A solution of the unpurified 225Ac complex obtained in theaforementioned step (1), and a solution containing a peptidemodifiedantibody (monovalent antibody) obtained in the samemanner as in Example 1 were each added to 0.1 mol / L argininecontaining0.1 mol / L histidine buffer (pH 6.0), and a clickreaction was performed at 37°C for 120 min to give 225Accomplex-labeled antibody. The amount of the 225Ac complex andthe amount of the peptide-modified antibody (monovalentantibody) were 85 nmol and 100 nmol (Examples 6 and 7),respectively, and the molar ratio of the first atomic group(DBCO) and the second atomic group (azide) was about 1:1.2.The reaction rate (%) of the unpurified 225Ac complex-labeledantibody is shown in the following Table 2. Here, the reactionrate (%) means the radiochemical purity (%) of the 225Ac complexlabeledantibody with respect to the labeling rate (%) in thecomplex formation step, and the labeling rate (%) means theamount of radioactivity (%) of the 225Ac complex with respect tothe charged radioactivity amount.Furthermore, a solution of the 225Ac complex-labeledantibody obtained by reacting at 37°C for 2 hr was purifiedusing ultrafiltration filter (manufactured by Merck, modelnumber: UFC505096). The radiochemical purity (RCP) andradiochemical yield (RCY) of the 225Ac complex-labeled antibodyafter purification are shown in the following Table 2.

[0153] The measurement method of the radiochemical purity andradiochemical yield of the 225Ac-labeled monovalent antibody wassimilar to that in Example 1.

[0154] [Table 2]DOTAGADBCOtrastuzumab azide 1:1.2 77% 93% 71%Ex. 7DOTAGADBCOrituximab azide 1:1.2 77% 95% 73%

[0155] [Example 8] Production of Tmab using 89Zr-labeled DOTAGA-DBCO(1. Complex formation step)The structure of the ligand used in this Example is thesame as that in the aforementioned formula (L1-4). This ligandwas dispersed in DMSO as a solvent to give a dispersioncontaining 0.33 mmol / L ligand. A reaction mixture of thedispersion (0.030 mL), and 89Zr ion-containing solution (0.1mol / L aqueous hydrochloric acid solution, radioactivityconcentration 181 MBq / mL, prepared from one manufactured byNihon Medi-Physics Co., Ltd., liquid amount 0.33 mL) 60 MBq asa radioactive metal source was reacted under heating conditionsto give a 89Zr complex solution. The molar ratio of the ligandand the radioactive metal ion was ligand:89Zr ion = about 250:1,and the heating temperature of the reaction mixture was set to70°C, and the heating time was set to 60 min.

[0156] The radiochemical purity of the obtained 89Zr complex wasmeasured by the following method. That is, a part of the 89Zrcomplex solution was developed by thin layer chromatography(manufactured by Agilent, model number: SGI0001, developingsolvent: acetonitrile / water mixed solution (volume ratio 1:1)),and then measured by radio γ-TLC Analyzer (manufactured byraytest, MODEL GITA Star PS). The percentage of theradioactivity (count) of the peak detected near the origin withrespect to the detected total radioactivity (count) was definedas the radiochemical purity (%) of the 89Zr complex. As aresult, the radiochemical purity of the 89Zr complex was 90%.The obtained 89Zr complex solution was used as it was in thelabeling step.

[0157] (2. Labeling step)A solution of the unpurified 89Zr complex obtained in theaforementioned step (1), and a solution containing a peptide20modified antibody (monovalent antibody) obtained in the samemanner as in Example 1 were each added without purification to0.1 mol / L arginine-containing 0.1 mol / L histidine buffer (pH6.0), and a click reaction was performed at 37°C for 120 min togive 89Zr complex-labeled antibody of Example 8. The amount ofthe 89Zr complex and the amount of the peptide-modifiedantibody (monovalent antibody) were each 100 nmol, and themolar ratio of the first atomic group (DBCO) and the secondatomic group (azide) was about 1:1. The reaction rate (%) ofthe unpurified 89Zr complex-labeled antibody of the Example isshown in the following Table 3. Here, the reaction rate (%)means the radiochemical purity (%) of the 89Zr complex-labeledantibody with respect to the labeling rate (%) in the complexformation step, and the labeling rate (%) means the amount ofradioactivity (%) of the 89Zr complex with respect to thecharged radioactivity amount.Furthermore, a solution of the 89Zr complex-labeledantibody obtained by reacting at 37°C for 2 hr was purifiedusing ultrafiltration filter (manufactured by Merck, modelnumber: UFC505096). The radiochemical purity (RCP) andradiochemical yield (RCY) of the 89Zr complex-labeled antibodyafter purification are shown in the following Table 3.

[0158] The measurement method of the radiochemical purity andradiochemical yield of the 89Zr complex-labeled antibody wassimilar to that in Example 8.

[0159] [Table 3]DOTAGADBCOtrastuzumab azide 1:1 52% 93% 43%

[0160] [Example 9] Production of Tmab using 89Zr-labeled DOTA-DBCO(1-1. Complex formation step)The structure of the ligand used in this Example is thesame as that in the aforementioned formula (L1-2). This ligandwas dispersed in DMSO as a solvent to give a dispersioncontaining 1 mmol / L ligand. A reaction mixture of thedispersion (0.1 mL), and 89Zr ion-containing solution (0.1mol / L aqueous hydrochloric acid solution, radioactivityconcentration 450 MBq / mL, prepared from one manufactured byOkayama University, liquid amount 0.1 mL) 45 MBq as aradioactive metal source was reacted under heating conditionsto give a 89Zr complex solution. The molar ratio of the ligandand the radioactive metal ion was ligand:89Zr ion = about10000:1, and the heating temperature of the reaction mixturewas set to 70°C, and the heating time was set to 60 min.

[0161] The radiochemical purity of the obtained 89Zr complex wasmeasured according to Example 1. As a result, theradiochemical purity of the 89Zr complex was 99%.

[0162] (1-2. Unreacted substance removal step)The obtained 89Zr complex solution was collected by highperformance liquid chromatography (HPLC), and unreacted DOTADBCOwas removed. The conditions of HPLC were as follows.detector: ultraviolet absorption spectrophotometer (measurementwavelength: 254 nm) / scintillation detector, column: XBridge C183.5 μm, 4.6x100 nm; manufactured by Waters, mobile phase A: 10mmol / L histidine buffer pH 6.5, mobile phase B: acetonitrilefor liquid chromatography, feed of mobile phase: the mixingratio of the mobile phase A and mobile phase B was changed asfollows to control the concentration gradient (A:B=90:10(0 min)->50:50(40 min) (vol% / vol%)), flow: 0.5 mL / min, collection peakretention time: about 32 min. The solvent was evaporated fromthe obtained collected solution to about 20 μL of the solutionand the solution was used in the labeling step. Theradiochemical yield (HPLC recovery rate) in the step ofremoving the unreacted substance of the 89Zr complex-labeledantibody is shown in the following Table 4. In the method formeasuring the radiochemical yield (HPLC recovery rate), thepercentage of radioactivity in the collected solution wasdefined as the HPLC recovery rate (%) in the unreactedsubstance removal step with respect to the amount ofradioactivity charged at the start of this step.

[0163] (2. Labeling step)A solution of the 89Zr complex obtained in theaforementioned each step, and a solution containing a peptidemodifiedantibody (monovalent antibody) obtained in the samemanner as in Example 1 were each added to 0.1 mol / L arginine35containing 0.1 mol / L histidine buffer (pH 6.0), and a clickreaction was performed at 37°C for 120 min to give 89Zr complexlabeledantibody. The labeling step reaction rate (%) of theunpurified 89Zr complex-labeled antibody of the Example isshown in the following Table 4. Here, the labeling stepreaction rate (%) means the amount of radioactivity (%) of the89Zr complex with respect to that of the HPLC collected solution.Furthermore, a solution of the 89Zr complex-labeledantibody obtained by reacting at 37°C for 2 hr was purifiedusing ultrafiltration filter (manufactured by Merck, modelnumber: UFC505096). The radiochemical purity (RCP) andradiochemical yield (RCY) of the 89Zr complex-labeled antibodyafter purification are shown in the following Table 4.

[0164] The measurement method of the radiochemical purity andradiochemical yield of the 89Zr complex-labeled antibodyfollowed that in Example 1.

[0165] [Table 4]DOTA-DBCO 57% trastuzumab azide 73% 98% 39%

[0166] While the present invention has been described above withreference to the embodiments, the present invention is notlimited to the above-mentioned embodiments. Various changesthat can be understood by those skilled in the art can be madeto the constitution and details of the present invention withinthe scope of the present invention.The contents disclosed in any publication cited herein,including patents and patent applications, are herebyincorporated in their entireties by reference, to the extentthat they have been disclosed herein.INDUSTRIAL APPLICABILITY

[0167] According to the present invention, high labelingefficiency of radioactive metals for antibodies can be achievedeven under mild reaction conditions.

[0168] This application is based on a patent application No.2019-191561 filed in Japan (filing date: October 18, 2019), thecontents of which are incorporated in full herein.SEQUENCE LISTING<110> Nihon Medi-Physics Co., Ltd.<120> Method for the production of radioactive metal-labeled antibodies<130> 093090<150> JP2019191561<151> 2019-10-18<160> 16<170> PatentIn version 3.5<210> 1<211> 13<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (1)<220><221> SITE<222> (6)..(6)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 1Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr1 5 10<210> 2<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (2)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 2Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 151His<210> 3<211> 13<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (3)<220><221> SITE<222> (6)..(6)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 3Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser1 5 10<210> 4<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (4)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 4Gly Pro Arg Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe1 5 10 15His<210> 5<211> 172<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (5)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 5Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15His<210> 6<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (6)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 6Gly Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15His<210> 7<211> 17<212> PRT<213> Artificial Sequence<220>3<223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (7)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 7Gly Pro Ser Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15His<210> 8<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (8)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 8Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Ser Phe1 5 10 15His<210> 9<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (9)4<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 9Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr His1 5 10 15His<210> 10<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (10)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 10Gly Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15Tyr<210> 11<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (11)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid5 residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 11Ser Pro Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15Tyr<210> 12<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (12)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 12Ser Asp Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15Tyr<210> 13<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (13)<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<400> 136Arg Gly Asn Cys Ala Tyr His Xaa Gly Gln Leu Val Trp Cys Thr Tyr1 5 10 15His<210> 14<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, paragraph

[0109] (14)<220><221> SITE<222> (2)..(2)<223> Xaa is a homosysteine residue.<220><221> SITE<222> (8)..(8)<223> Xaa is a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid or diaminopropionic acid.<220><221> SITE<222> (16)..(16)<223> Xaa is a homosysteine residue.<400> 14Gly Xaa Asp Cys Ala Tyr His Xaa Gly Glu Leu Val Trp Cys Thr Xaa1 5 10 15His<210> 15<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, P3<220><221> MOD_RES<222> (1)..(1)<223> linking to linker structure7<220><221> DISULFID<222> (4)..(14)<220><221> MOD_RES<222> (8)..(8)<223> modification with R1 structure<400> 15Gly Pro Asp Cys Ala Tyr His Lys Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15His<210> 16<211> 17<212> PRT<213> Artificial Sequence<220><223> Peptide for modifying antibody cited in the specification, P4<220><221> MOD_RES<222> (1)..(1)<223> linking to linker structure<220><221> MOD_RES<222> (4)..(14)<223> linking via linker structure<220><221> MOD_RES<222> (8)..(8)<223> modification with R2 structure<400> 16Gly Pro Asp Cys Ala Tyr His Lys Gly Glu Leu Val Trp Cys Thr Phe1 5 10 15His

Claims

1. A method for producing a radioactive metal-labeled antibody, comprising a step of conducting a click reaction of a radioactive metal complex and a peptide-modified antibody which is site-specifically modified with a peptide to produce the radioactive metal-labeled antibody, wherein the click reaction is performed between a first atomic group of the radioactive metal complex and a second atomic group directly or indirectly linked to the peptide, and the second atomic group is an atomic group containing an azide group, or an atomic group containing trans-cyclooctene.

2. The method for producing a radioactive metal-labeled antibody according to claim 1, wherein the peptide comprises an amino acid sequence represented by the following formula (i) and consisting of 13 to 17 amino acid residues, and has the second atomic group at the N-terminal or C-terminal of the peptide: (Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd)... (i) wherein Xa, Xb, Xc, and Xd are continuous X in the number of a, continuous X in the number of b, continuous X in the number of c, and continuous X in the number of d, respectively, X is an amino acid residue having neither a thiol group nor a haloacetyl group in the side chain, a, b, c and d are each independently an integer of not less than one and not more than 5, and satisfy a+b+c+d14, Xaa1 and Xaa3 are each independently an amino acid residue derived from an amino acid having a thiol group in the side chain, and they are bonded via a disulfide bond or their sulfide groups are bonded via a linker, or one is an amino acid residue derived from an amino acid having a thiol group in the side chain and the other is an amino acid residue derived from an amino acid having a haloacetyl group in the side chain, and they are bonded via a thioether bond, and Xaa2 is a lysine residue, an arginine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid, or a diamino propionic acid.

3. The method for producing a radioactive metal-labeled antibody according to claim 1 or 2, further comprising a step of reacting the ligand with the radioactive metal to form the radioactive metal complex.

4. The method for producing a radioactive metal-labeled antibody according to claim 3, wherein the ligand and the radioactive metal are reacted by heating.

5. The method for producing a radioactive metal-labeled antibody according to claim 3 or 4, wherein the ligand comprises a chelate site coordinated to the radioactive metal, and a modified site to which the first atomic group is bonded.

6. The production method according to claim 5, wherein the chelate site is represented by any one of the following formulas (A) to (K): in the formula (A), R11, R13 and R14 are each independently a group consisting of -(CH2)pCOOH, -(CH2)pC5H5N, -(CH2)pPO3H2, - (CH2)pCONH2 or -(CHCOOH)(CH2)pCOOH, one of R12 and R15 is a hydrogen atom, a carboxyl group, or a carboxyalkyl group having 2 or 3 carbon atoms, the other is a group bonded to the modified site, and p is an integer of not less than 0 and not more than 3, in the formula (B), R21, R22, R23 and R24 are each independently a carboxyl group or a carboxyalkyl group having a carbon number of 2 or 3, and any one group of R21, R22, R23 or R24 is bonded to the modified site, in the formula (C), R31, R32, R33 and R34 are each independently a group composed of an atomic group having a hydrogen atom and not less than 2 and not more than 10 carbon atoms, and optionally containing a nitrogen atom or an oxygen atom, and R35 is a group bonded to the modified site, in the formula (D), one of R41 and R42 is a group composed of an atomic group having a hydrogen atom and not less than 5 and not more than 20 carbon atoms and containing one or more kinds selected from nitrogen atom, oxygen atom and sulfur atom, and the other is a group bonded to the modified site, in the formula (E), R51, R52, R53, R54 and R55 are each independently a carboxyl group, or a carboxyalkyl group having a carbon atom number of 2 or 3, and any one group of R51, R52, R53, R54 or R55 is bonded to the modified site, in the formula (F), R61, R62, R63, R64, R65 and R66 are each independently a carboxyl group, or carboxyalkyl group having a carbon atom number of 2 or 3, and R67 is a group bonded to the modified site, in the formula (G), R71 and R72 are -O(CH2CH2O)nCH3 (n is an integer of not less than 1 and not more than 5), R73, R75, R76 and R78 are each independently an alkyl group having a carbon atom number of not less than 1 and not more than 5, one of R74 and R77 is a hydroxyalkyl group having a carbon number of not less than 1 and not more than 5, and the other is a group bonded to the modified site, in the formula (H), R81 and R82 are each independently an alkyl group having a carbon number of not less than 1 and not more than 5, a terminal of the alkyl group may be substituted by a pyridyl group substituted by one or more carboxyl groups, R87 is -CHOH or -C=O, any one group of R81, R82 or R87 is a group bonded to the modified site, R83 and R84 are optionally substituted pyridinyl groups, R85 and R86 are each independently -COORa, and Ra is an alkyl group having a carbon number of not less than 1 and not more than 5, in the formula (I), R91, R92, R93 and R94 are each independently -OCH2COOH, any one group of R91, R92, R93 or R94 is a group bonded to the modified site, and R95, R96, R97 and R98 are each independently an alkyl group having a carbon number of not less than 1 and not more than 6, and in the formula (J), R101, R102 and R103 are each independently a carboxyl group or a carboxyalkyl group having a carbon atom number of 2 or 3, or at least one of R101, R102 and R103 in the formula (J) is a group bonded to the modified site and the other group is a carboxyl group, or a carboxyalkyl group having a carbon atom number of 2 or 3.

7. The method for producing a radioactive metal-labeled antibody according to any one of claims 1 to 6, wherein the radioactive metal is 44Sc, 51Cr, 57Co, 58Co, 60Co, 59Fe, 67Ga, 68Ga, 64Cu, 67Cu, 89Sr, 89Zr, 90Y, 99mTc, 103Ru, 111In, 153Sm, 165Dy, 166Ho, 177Lu, 186Re, 188Re, 198Au, 201Tl, 197Hg, 203Hg, 212Bi, 213Bi, 212Pb, 227Th or 225Ac.

8. The method for producing a radioactive metal-labeled antibody according to claim 7, wherein the radioactive metal is an α ray-emitting nuclide.

9. The method for producing a radioactive metal-labeled antibody according to any one of claims 1 to 8, wherein the click reaction is performed at 50°C or below.

10. The method for producing a radioactive metal-labeled antibody according to any one of claims 1 to 9, wherein the peptide-modified antibody is site-specifically modified with 1 molecule or 2 molecules of peptide per 1 molecule of the antibody.

11. A radioactive metal-labeled antibody site-specifically modified with a peptide, wherein the radioactive metal complex is directly or indirectly linked to the peptide, and a triazole skeleton-containing structure represented by the following formula (10a) is present between the peptide and the radioactive metal complex, or a pyridazine skeleton-containing structure is present between the peptide and the radioactive metal complex: wherein R1A is a binding site with a modified site or a chelate site, and R2A is a binding site with a peptide.

12. The radioactive metal-labeled antibody according to claim 11, comprising a pyridazine skeleton-containing structure represented by the following formula (10c) between the peptide and the radioactive metal complex: wherein one of R3A and R4A is a hydrogen atom, a methyl group, a phenyl group or a pyridyl group, and the other is a binding site with a modified site or a chelate site, and R5A is a linking site with a peptide.

13. A chelate linker comprising a chelate site coordinated to a radioactive metal, and a modified site to which a first atomic group capable of click reaction is bonded, wherein the first atomic group is an atomic group represented by the following formula (1a) or (1b): in the formula (1a), R1 is a binding site with a modified site or a chelate site, and in the formula (1b), one of R3 and R4 is a binding site with a modified site or a chelate site, and the other is a hydrogen atom, a methyl group, a phenyl group or a pyridyl group.

14. A peptide-modified antibody represented by the following formula (i) and site-specifically modified by a peptide comprising an amino acid sequence consisting of 13 to 17 amino acid residues, which antibody comprising a second atomic group capable of click reaction is linked to the N-terminal or C-terminal of the peptide, wherein the second atomic group is an atomic group represented by the following formula (2a) or (2b): (Xa)-Xaa1-(Xb)-Xaa2-(Xc)-Xaa3-(Xd)... (i) wherein Xa, Xb, Xc, and Xd are continuous X in the number of a, continuous X in the number of b, continuous X in the number of c, and continuous X in the number of d, respectively, X is an amino acid residue having neither a thiol group nor a haloacetyl group in the side chain, a, b, c and d are each independently an integer of not less than one and not more than 5, and satisfy a+b+c+d14, Xaa1 and Xaa3 are each independently an amino acid residue derived from an amino acid having a thiol group in the side chain, and they are bonded via a disulfide bond or their sulfide groups are bonded via a linker, or one is an amino acid residue derived from an amino acid having a thiol group in the side chain and the other is an amino acid residue derived from an amino acid having a haloacetyl group in the side chain, and they are bonded via a thioether bond, and Xaa2 is a lysine residue, an arginine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, a 2-aminosuberic acid, or a diamino propionic acid, in the formula (2a), R2 is a linking site with the N-terminal or C-terminal of the peptide, and in the formula (2b), R5 is a linking site with the N-terminal or C-terminal of the peptide.

15. The antibody according to claim 14, wherein the peptidemodified antibody is site-specifically modified with 1 molecule or 2 molecules of the peptide per 1 molecule of the antibody.